Pediatrix Medical Group (MD) Q3 2026: Buybacks Drive EPS Beat
As seen on the 24/7 Wall St. homepage on October 29, 2026.
Buybacks are doing the heavy lifting at Pediatrix: $83 million repurchased in the quarter cut the diluted share count to 79.7 million, pushing adjusted EPS past expectations even as adjusted EBITDA slipped. Revenue came in just above expectations, and full-year EBITDA guidance of $290 million to $300 million was reiterated.
Continue ReadingShow less
Pediatrix Medical Group reported adjusted EPS of $0.72 for the third quarter of 2026, beating expectations on both earnings and revenue.
That beat leans on buybacks: $83 million of repurchases cut the diluted share count to 79.7 million from 85.6 million a year ago, amplifying per-share earnings while the operating picture stayed mixed.
Sponsored
Adjusted EBITDA slipped to $85.5 million as clinical salaries and incentive compensation ate into margins, pushing EBITDA in the opposite direction from EPS. CEO Mark Ordan pointed to volume and pricing running ahead of the company's own expectations, with a favorable payor mix and higher neonatology acuity providing some offset.
Management reiterated its full-year 2026 adjusted EBITDA target of $290 million to $300 million, offering no lift despite the quarterly beat. The question for investors is whether buyback-driven EPS momentum holds as salary costs outpace revenue growth.
Sources
Mentioned: MD